Abstract:Background Hepatic caveolin-1 (CAV1) is reduced in cholesterol gallstone disease (CGD). Mice with CAV1 deficiency were prone to develop CGD. However, it remains unknown whether restored hepatic CAV1 expression prevents the development of CGD. Methods C57BL/6 mice were injected with adeno-associated virus 2/8 (AAV2/8) vectors carrying the CAV1 gene ((AAV2/8)CAV1) via intravenous (i.v.) or intraperitoneal (i.p.) route and then subjected to a lithogenic diet (LD) for 8 weeks. Uninjected mice were used as controls. The functional consequences of rescuing CAV1 expression by either i.v. or i.p. (AAV2/8)CAV1 treatment for CGD prevention and its subsequent molecular mechanisms were examined. Results CAV1 expression was reduced in the liver and gallbladder of LD-fed CGD mice. We discovered that (AAV2/8)CAV1 i.p. delivery results in higher transduction efficiency in the gallbladder than tail vein administration. Although either i.v. or i.p. injection of (AAV2/8)CAV1 improved liver lipid metabolic abnormalities in CGD mice but did not affect LD feeding-induced bile cholesterol supersaturation. In comparison with i.v. administration route, i.p. administration of (AAV2/8)CAV1 obviously increased CAV1 protein levels in the gallbladder of LD-fed mice, and i.p. delivery of (AAV2/8)CAV1 partially improved gallbladder cholecystokinin receptor (CCKAR) responsiveness and impeded bile cholesterol nucleation via the activation of adenosine monophosphate-activated protein kinase (AMPK) signaling, which induced a reduction in gallbladder mucin-1 (MUC1) and MUC5ac expression and gallbladder cholesterol accumulation. Conclusion CGD prevention by i.p. (AAV2/8)CAV1 injection in LD-fed mice was associated with the improvement of gallbladder stasis, which again supported the notion that supersaturated bile is required but not sufficient for the formation of cholesterol gallstones. Additionally, AAV treatment via the local i.p. injection offers particular advantages over the systemic i.v. route for much more effective gallbladder gene delivery, which will be an excellent tool for conducting preclinical functional studies on the maintenance of normal gallbladder function to prevent CGD.

Adeno-associated Virus-Based Caveolin-1 Delivery Via Different Routes for the Prevention of Cholesterol Gallstone Formation

Expression and Its Significance of Caveolin–1 in Liver and Gallbladder of Gallstone Mice Model

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

CAV1 Prevents Gallbladder Cholesterol Crystallization by Regulating Biosynthesis and Transport of Bile Salts

Association of Caveolin-3 and Cholecystokinin A Receptor with Cholesterol Gallstone Disease in Mice

Differences Between Hepatic and Biliary Lipid Metabolism and Secretion in Genetically Gallstone-Susceptible and Gallstone-Resistant Mice

Caveolin1 Protects Against Diet Induced Hepatic Lipid Accumulation in Mice.

Impaired regulation of sterol regulatory element binding protein 2 in cholesterol gallstone-susceptible mice.

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

Activation of Constitutive Androstane Receptor Prevents Cholesterol Gallstone Formation

PPARγ1-Induced Caveolin-1 Enhances Cholesterol Efflux and Attenuates Atherosclerosis in Apolipoprotein E-Deficient Mice

Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.

Characteristics of Mrna Levels of Hepatic Cholesterol Metabolism Regulatory Enzymes in Genetically Gallstone-Susceptible and Resistant Mice

Hyodeoxycholic acid attenuates cholesterol gallstone formation via modulation of bile acid metabolism and gut microbiota

Ursodeoxycholic Acid Protects Interstitial Cajal-like Cells in the Gallbladder from Undergoing Apoptosis by Inhibiting TNF-α Expression

Upregulation of Caveolin-1 and SR-B1 in Mice with Non-Alcoholic Fatty Liver Disease

Peroxisome Proliferator-Activated Receptor-γ Prevents Cholesterol Gallstone Formation in C57bl Mice by Regulating Bile Acid Synthesis and Enterohepatic Circulation

Caveolin-1 Alleviates Acetaminophen-Induced Fat Accumulation in Non-Alcoholic Fatty Liver Disease by Enhancing Hepatic Antioxidant Ability via Activating AMPK Pathway

Caveolin-1 attenuates acetaminophen aggravated lipid accumulation in alcoholic fatty liver by activating mitophagy via the Pink-1/Parkin pathway

Dietary diosgenin transcriptionally down-regulated intestinal NPC1L1 expression to prevent cholesterol gallstone formation in mice

Caveolin-1 Ameliorates Hepatic Injury in Non-Alcoholic Fatty Liver Disease by Inhibiting Ferroptosis Via the NOX4/ROS/GPX4 Pathway